A prospective open label, multicenter study to evaluate the feasibility and side effects of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days by mouth difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia.
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability in Combination with Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors
The purpose of this study is to test the effectiveness of using an investigational agent called DFMO along with etoposide for Neuroblastoma.
This is an open-label, sequential-arm, Phase 1b/2 clinical trial of bempegaldesleukin in combination with nivolumab in pediatric participants with malignancies that are refractory, relapsed, or participants for whom curative treatments are lacking.
This study will evaluate the use of Difluoromethylornithine (DFMO) as a single agent in patients with high risk medulloblastoma after completing therapy as maintenance therapy with the hopes of preventing relapse.
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEK) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
Treatment of cHL in children and young adults – evaluation of pembrolizumab in a subgroup with inadequate early response to frontline chemotherapy.